Aromatase Inhibitors

Aromatase inhibitors (AIs) have quickly become standard treatments for postmenopausal women with estrogen-receptor-positive breast cancer.

More: What Are Aromatase Inhibitors?

In 2005, Breast Cancer Action launched an online survey to collect information from women about AI side effects they were experiencing. In 2007, BCA released a preliminary report called “Side Effects Revealed: Women’s Experience With Aromatase Inhibitors” based on the first 612 responses.

In June 2008, BCA released the follow-up report, Side Effects Revisited: Women’s Experiences with Aromatase Inhibitors based on nearly 1,200 responses.

Here at BCA, we understand that patients often recognize emerging side effects before the medical community does. Through these reports, we hope to encourage additional research on the long-term side effects of AIs.

These reports are dedicated to the women who generously took the time to respond to BCA’s Aromatase Inhibitor Side Effects Survey and to everyone who seeks to make informed decisions about the care they receive.

Read comments from survey respondents